Last reviewed · How we verify
KDF1901 — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
KDF1901 (KDF1901) — Kyungdong Pharmaceutical Co., Ltd.. KDF1901 is an investigational therapeutic agent in phase 3 development by Kyungdong Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| KDF1901 TARGET | KDF1901 | Kyungdong Pharmaceutical Co., Ltd. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). KDF1901 — Competitive Intelligence Brief. https://druglandscape.com/ci/kdf1901. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab